DRKS00012599CompletedPhase 2
Cisplatin/Etoposide or Paclitaxel/Carboplatin with Concurrent Radiation Therapy in Stage IIIB Non-Small Cell Lung Cancer: A One-Year Randomized Trial at a Low-Resource Setting - Shuayb CCRT Trial
Oncology & Radiotherapy Centre, Square Hospitals Ltd.0 sites60 target enrollmentStarted: July 20, 2017Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 60
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized controlled study
- Masking
- Blinded (masking used)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (—)
- Sex
- All
Inclusion Criteria
- •Inclusion criteria included Non-small cell lung cancer proved by pathology or cytology; inoperable AJCC stage IIIB prior to the initiation of treatment; age: 18 to 75; Eastern Cooperative Oncology Group (ECOG) performance status =2; lose of weight <10% during 6 months; biochemical tests values: WBC =3.5×109/L, neutrophils =1.5×109/L, platelets =100×109/L, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin =1.5 × the upper limit of the institutional normal range; creatinine concentration =120 umol/L, and creatinine clearance=50 ml/min; no serious diseases of important organs; written informed consent signed prior to enrollment.
Exclusion Criteria
- •Exclusion Criteria included pretreatment with radiotherapy, chemotherapy or biological agents; pregnant or lactating woman; serious diseases (include significant cardiovascular disease or uncontrolled diabetes) of important organs; other malignancies; active uncontrolled infection; joined in other clinical trial.
Investigators
Similar Trials
Recruiting
Phase 3
To Compare Carboplatin/ Paclitaxel with Cisplatin/ Etoposide in advanced Non Small Cell Lung cancer (NSCLC).CTRI/2020/03/023770Tata Memorial Hospital
Completed
Not Applicable
Carboplatin versus etoposide/cisplatin for advanced metastatic seminomaTesticularCancerISRCTN27827390Medical Research Council (MRC) (UK)112
Completed
Phase 2
Carboplatin and nab-Paclitaxel as first-line treatment in patients with advanced non-small cell lung cancer with interstitial lung disease (HOT1302)on-small cell lung cancerJPRN-UMIN000012901Hokkaido Lung Cancer Clinical Study Group36
Completed
Not Applicable
Paclitaxel plus carboplatin for advanced or recurrent carcinosarcoma of the uterus in Japan.advanced or recurrent carcinosarcomaJPRN-UMIN000008390Gynecology, Tohoku University Hospital35
Completed
Not Applicable
CP therapy (Carboplatin and Paclitaxel) for advansed malignant melanomamalignant melanomaJPRN-UMIN000004073Kumamoto University50